• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Oncology Letters >Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy
【2h】

Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy

机译：C-反应蛋白在中度转移性肾细胞癌分子靶向治疗中的预后意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The present study aimed to investigate the impact of pre-treatment C-reactive protein (CRP) levels on the prediction of prognosis in patients with metastatic renal cell carcinoma (mRCC), who were classified as intermediate-risk patients using the Memorial Sloan Kettering Cancer Center (MSKCC) risk classification and who received molecular targeted therapy. The oncological outcome of 140 patients with mRCC who underwent molecular targeted therapy was analyzed. Patients were divided into favorable-, intermediate- and poor-risk groups (groups F, I and P, respectively) based on the MSKCC risk classification. The patients in group I were then further classified into two groups based on pre-treatment serum CRP levels. The overall survival (OS) rates of the patients in these groups were then assessed. The OS rate of the patients in group I with normal pre-treatment CRP levels was found to be significantly increased compared with that of patients with high pre-treatment CRP levels (P<0.0001), while there was no significant difference in the OS rate in the patients with normal pre-treatment CRP levels in group I compared with those in group F. Multivariate analyses revealed that high pre-treatment CRP levels were an independent prognostic factor for OS in the patients in group I (P<0.0001; hazard ratio, 3.898). Thus, pre-treatment CRP levels may be a candidate predictor for OS in patients with intermediate-risk mRCC.
机译：本研究旨在探讨转移性肾细胞癌（mRCC）患者的治疗前C反应蛋白（CRP）水平对预后预测的影响，这些患者使用纪念斯隆·凯特琳纪念堂（Memorial Sloan Kettering Cancer）被分类为中危患者中心（MSKCC）风险分类以及接受分子靶向治疗的人员。分析了140例接受分子靶向治疗的mRCC患者的肿瘤学结局。根据MSKCC风险分类，将患者分为高危，中危和低危组（分别为F，I和P组）。然后根据治疗前血清CRP水平将I组患者进一步分为两组。然后评估这些组中患者的总生存率。与治疗前CRP水平高的患者相比，治疗前CRP水平正常的I组患者的OS率显着增加（P <0.0001），但OS率无显着差异与F组相比，I组中治疗前CRP水平正常的患者。多因素分析显示，I组中治疗前CRP水平高是OS的独立预后因素（P <0.0001；危险比） ，3.898）。因此，治疗前CRP水平可能是中危mRCC患者OS的候选指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号